Author

Tiantian Zeng

Observed names: T Zeng, Zeng, Tiantian

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Guangdong Medical College, Central People's Hospital of Zhanjiang

OpenAlex ID: A5111740144

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

2024 · Paul Scott, Miwa Haranaka, et al. · Clinical Infectious Diseases · 42

The dissemination mode of drug-resistant genes in Enterobacter cloacae

2015 · J Liu, T Zeng, et al. · Indian Journal of Medical Microbiology · 9

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons

2026 · Heather J. Zar, Louis J. Bont, et al. · Archives of Pediatrics and Adolescent Medicine · 4

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13)

2026 · Vinita Jagannath, Jayani Pathirana, et al. · Human Vaccines & Immunotherapeutics · 2

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13)

2026 · Jagannath, Vinita, Pathirana, Jayani, et al. · Figshare

Works count: 5

Citation count: 57

H-index: 3

I10-index: 1